Bellerophon Therapeutics WKN: A2PZZR ISIN: US0787713009 Kürzel: BLPH Forum: Aktien Thema: Hauptdiskussion

Instis weiterhin fett investiert bei 13 dollar, entspannt euch einfach😅 hoffentlich ist covinox gut. Ich gehe davon aus, weil sie wollen ein „operation warp speed“

Ich predige hier seit monaten, blph langfristig totale komplettexplosion, kurzfristig abhängig was bei covinox passiert

Des Weiteren am ende des Jahres eine andere Studie. —> Phase 2 Clinical Study: Bellerophon is continuing enrollment in a Phase 2 dose escalation study in PH-Sarc, and anticipates the availability of top-line data around the end of 2020.

Heute kommen die p2 ergebniss, von der anderen studie also punkt 3

1) In support of our development and manufacturing plans in COVID-19, we have applied for government funding and are in discussions with a number of federal agencies, including Operation Warp Speed.” 2) “We are pleased with the rate of enrollment in our ongoing COViNOX Phase 3 clinical trial of INOpulse for the treatment of COVID-19. The results of a planned interim analysis are expected shortly, as the first 100 patients have now completed their 28-day assessment period. 3) “In our pivotal Phase 3 REBUILD trial for fibrotic interstitial lung disease (fILD) patients at risk of associated pulmonary hypertension, we initiated the first clinical research sites, allowing us to begin patient enrollment,”

Ich glaube du hast die Nachricht nicht gelesen

😂.. Wäre zu wünschen...

Blph vor komplettexplosion

Nein aber die kommt auch bald

Welche? Die covid??

Heute kommen noch daten

Kann wahrscheinlich heute nicht mehr auf ähnlich Kurse hoffen...

HAT mein stop buy ausgelöst und mittlerweile bin ich wieder darunter 😭..

Weiss jemand was den peak von über 20 Prozent ausgelöst hat?

COVID-19 (Coronavirus) COViNOX Phase 3 Study: Bellerophon continues to enroll patients in the Company’s ongoing Phase 3 clinical study of INOpulse inhaled nitric oxide (iNO) therapy for the treatment of COVID-19 and anticipates the availability of the results from a planned interim analysis shortly. The Phase 3 randomized, placebo-controlled COViNOX study is evaluating the efficacy and safety of the investigational INOpulse therapy in patients diagnosed with COVID-19 who require supplemental oxygen. The COViNOX protocol utilizes an adaptive design and aims to enroll up to 500 patients with COVID-19 who will be treated with either INOpulse or placebo at major U.S. hospitals. The primary endpoint will assess the proportion of subjects that had respiratory failure or mortality, which should allow the trial to serve as a registrational study for approval. In parallel, Bellerophon has applied for government funding and remains in ongoing discussions with multiple federal agencies to support the Company’s development and manufacturing plans in COVID-19.

https://www.globenewswire.com/news-release/2020/11/05/2121080/0/en/Bellerophon-Provides-Clinical-Program-Update-and-Reports-Third-Quarter-2020-Financial-Results.html